Lisa La on Diabetes Management in Patients with Multiple Myeloma

A descriptive analysis of the CONNECT MM Registry (NCT01081028), a disease registry for patients with newly diagnosed symptomatic multiple myeloma, that was presented at the 2020 American Society of Hematology Annual Meeting & Exposition highlighted an unmet need for providing better supportive care for the management of diabetes in patients with multiple myeloma in order to further improve survival outcomes.

The aim of the study was to evaluate differences in baseline characteristics, treatment patterns, and survival outcomes in patients with diabetes versus those without who were enrolled in the registry.

In an interview with CancerNetwork®, Lisa La, director of clinical research in the Center for Cancer Care at White Plains Hospital, discussed the results of the study further and what led to this research.

Transcription:

The study that I put together and analyzed for the poster presentation was specifically looking at [patients with] myeloma and diabetes and [their] outcomes. There wasn’t a lot out there in terms of articles or any generalizable data. There were some journal [articles] on single-center studies talking about patients [with diabetes having] shorter [progression-free survival] and [overall survival], but it wasn’t really generalizable to the United States. Our outcomes from this were that patients had shorter progression-free survival and shorter overall survival. They tended to be on the older side and also had poor baseline characteristics.

Reference:

La L, Jagannath S, Ailawadhi S, et al. Clinical features and survival outcomes in diabetic patients with newly diagnosed multiple myeloma (NDMM) enrolled in the Connect® MM Registry. Blood. 2020;136(suppl 1):49-50. doi:10.1182/blood-2020-137309.